Clene Inc.
No enriched coverage for $CLNN in the last 7 days.
No SEC Form 4 filings for $CLNN in the last 30 days.
Chidozie Ugwumba has reported a 9.7% beneficial ownership stake in Clene Inc. (CLNN), totaling 1,351,071 shares. This includes both issued common stock and shares issuable upon the exercise of immediately exercisable Tranche A, Tranche B, and Common Stock Purchase Warrants. The filing is an amendment to a Schedule 13G and references 12,778,307 shares outstanding as of May 14, 2026, as per Clene Inc.'s Form 10-Q.
SymBiosis II LLC, an entity associated with major Clene (NASDAQ: CLNN) shareholder Ugwumba Chidozie, reported selling a total of 78,679 shares of Clene Inc. common stock in two open-market transactions. These sales occurred on May 1, 2026, for 5,795 shares at $6.01, and on May 4, 2026, for 72,884 shares at $6.80. Following these transactions, SymBiosis II LLC indirectly holds 198,890 shares of Clene Inc.
A 10% owner of Clene (NASDAQ: CLNN), through the associated entity SymBiosis II, LLC, sold 19,497 shares of common stock in open-market transactions over three days in late April 2026. The sales were executed at prices ranging from $5.63 to $6.08 per share. Following these transactions, SymBiosis II, LLC still indirectly holds 277,569 shares of Clene Common Stock.
